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Introduction
Hepatitis D virus (HDV) is a transmissible agent dis-
covered in 1977.1 It requires helper functions from hepati-
tis B virus (HBV) for virion assembly and propagation.2 
This unique human virus is associated with co-infections 
or super infections of patients already infected with HBV. 
Coexisting infection with HDV tends to accelerate the 
progress of chronic HBV infection towards chronic hepa-
titis, cirrhosis and hepatocellular carcinoma.3 Hepatitis 
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Despite the decreasing trend in hepatitis D virus (HDV) infection worldwide, the importance of this 
disease cannot be underestimated. The aim of this study was to evaluate patients positive for HBsAg with 
respect to HDV infection and related factors. Patients with chronic hepatitis B who presented at Hamedan 
Province Hepatitis Community Center in 2002–2007 were included. A questionnaire covering demo-
graphic variables and history of hepatic disease was completed for each patient. Necessary tests were 
performed and antibodies to HDV were measured using an enzyme-linked immunosorbent assay. Of 81 
HBsAg positive patients, 14 (17.3%) contained anti-HDV IgG. Only one of the patients with anti-HDV 
IgM was positive for HBsAg. Of the anti-HDV IgG positive patients, two (14.3%) were women. Among the 
women examined in this study, 24 (35.8%) were anti-HDV IgG negative (p = 0.21), and of these, six (42.8%) 
were HBeAg positive while 17 (25.4%) of the anti-HDV IgG negative women were positive for HBeAg 
(p = 0.16). The prevalence of chronic hepatitis B among anti-HDV IgG positive and negative patients was 
28.6% and 39.2% respectively (p = 0.31). Because of the relatively high rate of hepatitis B virus (HBV) and 
HDV co-infection in our study subjects, it is vital that healthcare providers and policy makers to recognize 
the risk factors associated with this HBV and HDV co-infection as well as the reasons for this increased 
anti-HDV serology in HBV carriers.
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caused by HDV may result in a 3-fold increase in hepato-
cellular carcinoma development and 2-fold increase in 
mortality compared with HBV infection without HDV.4
HBV infection is a global health problem; over 350 
million people worldwide are chronic carriers of the virus. 
It has been estimated that approximately 5% of the global 
HBsAg carriers are also co-infected with HDV. Thus there 
are 10–15 million HDV carriers worldwide.5,6 The geo-
graphic distribution of HDV infection might be expected 
to mirror that of HBV. Nevertheless, the rate of HDV in-
fection is not a simple reflection of HBV infection, as 
areas endemic for HBV may be almost HDV-free.7 HDV 
prevalence in Italy, Eastern Europe and western Asia is 
higher than the rest of the world8 with infection apparently 
endemic in the Middle East.9
High prevalence areas of HDV infection include Italy, 
parts of Eastern Europe, the Amazon basin, Venezuela, 
Columbia, some Pacific Islands, Pakistan and Western 
Asia.7,10–13 It is estimated that each year, 7,500 HDV in-
fections occur in the United States.11 New foci of infec-
tion have been identified on the island of Okinawa in 
Japan,14 villages in China, northern India15 and southern 
Albania.16 The subtropical area in South America remains 
an important potential reservoir for new outbreaks of 
HDV infection.17 From different studies in Iran, 2.4–5.8% 
of HBV carriers were reportedly HDV positive.18–20 Changes 
in HDV epidemiology have occurred over the past 10 years 
with several studies suggesting that the prevalence of 
HDV infection has declined over the past decades.8,21
Overall, HDV infection is still an important public 
health problem worldwide and remains a major cause of 
mortality and liver transplantation. The purpose of this 
study was to evaluate the risk factors and prevalence of 
HDV in HBV-infected individuals in Iran.
Methods
A cross-sectional study was conducted in the Hamedan 
province of Iran from 2002 to 2007. All HBV-infected in-
dividuals enlisted in the Hamedan hepatitis association 
from January 2002 to January 2007 who were willing 
to sign informed written consent participated in the 
study. A questionnaire including age, sex, history of 
intravenous drug abuse, history of blood transfusion, 
mother carrier status of hepatitis B, liver function tests, 
chronicity or carrier state was administered. Abnormality 
in alanine transaminase levels for at least 6 months in 
HBsAg positive patients was considered to be chronic 
hepatitis B.
Approximately 5 mL of blood was collected from 
each participant. Serum samples were tested for the pres-
ence of anti-HDV antibodies (IgM, IgG) using an HDV 
antibody enzyme-linked immunosorbent assay (ETI-AB-
DELTAK-2; Diasorin, Dietzenbach, Germany). Other lab-
oratory tests such as complete blood count and liver 
function tests (aspartate transaminase, alanine transami-
nase, alkaline phosphatase, bilirubin and prothrombin 
time) were also performed. The study was approved by the 
ethics committee of the Hamedan University of Medical 
Sciences in Hamedan, Iran.
Statistical analysis
Data analysis was performed using SPSS version 11.0 
(SPSS Inc., Chicago, IL, USA). Qualitative or quantitative 
variables were analyzed using non-parametric tests, the 
χ2 test and Fisher’s exact test. Quantitative variables were 
also analyzed with the Student’s t test. A p value < 0.05 was 
considered significant.
Results
Of the 81 HBsAg-positive individuals tested for the pres-
ence of anti-HDV antibodies, 55 (67.9%) were males. The 
average age was 35.6 ± 14.7 years and most (61.7%) were 
under 30 years old. Thirty participants (37.0%) suffered 
from chronic hepatitis and the rest were carriers. Anti-HDV 
IgG was found in 14 (17.3%) individuals. Only one partici-
pant was positive for anti-HDV IgM. Female constituted 
14.3% of the 14 anti-HDV IgG positive participants and 
35.8% of the anti-HDV negative participants. The difference 
was not statistically significant (p = 0.21).
Factors such as age, sex, the mother’s carrier state of 
hepatitis B, history of blood transfusion, history of intra-
venous drug abuse, chronic hepatitis or carrier state, liver 
enzymes and positive HBeAg serology were analyzed to 
determine a correlation with positive or negative anti-HDV 
serology. Of the above mentioned factors, only intravenous 
drug abusers showed a statistically significant difference 
between the two groups. The Table shows the relationship 
of different factors to anti-HDV serology.
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Discussion
This study demonstrates that the prevalence of anti-HDV 
seropositivity (17.3%) in the Hamedan province of Iran 
is higher than the level reported by the World Health 
Organization (5%). It is also higher than previous studies 
carried out in this region19 and those carried out in other 
parts of Iran.18,21 This may be due to the high number 
of intravenous drug abuse subjects in our study.
In a study carried out in Tehran in 1988, 2.5% of HBV 
carriers (n = 120) were reported to be HDV positive.18 
Amini et al found this proportion to be 2.4% in Hamedan 
in 1993 (n = 123).11 In a more recent study in 2005, 5.8% 
of HBsAg positive individuals were found to be HDV 
infected in Golestan province (n = 164).20
Other studies conducted in the Middle East region 
have reported different results. A study by Njoh et al22 in 
Saudi Arabia found that 13.6% of HBV carriers (n = 81) 
were also positive for anti-HDV. In Pakistan (n = 246)23 
and Turkey (n = 889)24, 26.8% and 6%, respectively, were 
HBV carriers and HDV positive.
There are areas with high prevalence of HBV infection 
but relatively low prevalence, if any, of HDV infection, sug-
gesting that other factors, such as age at HBV infection, 
may determine the acquisition of HDV infection. As an 
example, for Alaskan Natives in which HBV infection oc-
curs during infancy and childhood, the prevalence of HDV 
infection is negligible despite the endemic nature of HBV. 
HDV appears to be endemic in the Middle East, but again 
its distribution bears little relationship to that of HBV.25 
In this study, the prevalence of anti-HDV seropositivity 
was higher in males compared with females. Risk factors 
such as a greater possibility of multiple partners among 
males compared with females in Islamic countries like 
Iran, and intravenous drug use can be explained as possi-
ble causes of this discrepancy.
Some countries have witnessed a declining trend in 
the prevalence of HDV infection.10,18,26,27 HDV was found 
to be responsible for a high proportion of cases of HBV-
related acute and chronic liver disorders in southern Europe 
during the 1970s. However, by the 1990s, its seropreva-
lence had substantially declined.28 In Italy, the prevalence 
of anti-HDV among HBsAg carriers with liver diseases de-
creased from 25% in 1983 to 14% in 1992.28 A multicenter 
Italian study29 conducted in 1997 reported HDV positiv-
ity of only 8.3% in HBsAg positive patients — a figure much 
lower than those observed in the previous two multicenter 
surveys performed in 1987 and 1992 (23% and 14%, re-
spectively). The authors estimated that from 1987 to 1997, 
the rate of decrease in the proportion of HBsAg carriers 
with anti-HDV was approximately 1.5% per year.29 A similar 
decrease (from 15.1% in 1983 to 7.1% in 1992) has also been 
reported in Spain. In Taiwan, Huo et al10 reported a de-
crease in HDV infection from 23.7% in 1983 to 4.2% in 1995.
Improvements in socioeconomic conditions, an in-
creased awareness of the risk of transmitting infectious 
Table. Age, sex, chronic hepatitis or carrier state, liver enzymes and positive HBeAg serology compared with anti-hepatitis D virus 
positive and negative groupsa
Characteristics anti-HDV IgG positive (n = 14) anti-HDV IgG negative (n = 67) p 
Sex, male 12 (85.7) 43 (64.2) 0.41
Age (yr) 36.9 ± 12.6 35.4 ± 15.6 0.77
Mother’s carrier state 9 (64.2) 24 (35.8) 0.03
Blood transfusion 1 (7.1) 10 (14.9) 0.21
Intravenous drug abuser 2 (14.3) 5 (7.4) 0.21
HBeAg positive 6 (42.8) 17 (25.4) 0.16
Chronic hepatitis B  4 (28.6) 26 (38.8) 0.31
Hepatitis B carrier 10 (71.4) 38 (58.5) 0.41
Serum ALT (IU/L) 40.1 ± 26.0 55.6 ± 38.0 0.37
Serum AST (IU/L) 32.9 ± 9.9 41.9 ± 22.0 0.34
aData presented as n (%) or mean ± standard deviation. IgG = immunoglobulin G; ALT = alanine transaminase; AST = aspartate transaminase.
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diseases fostered by acquired immunodeficiency syndrome 
prevention policy, promotion of disposable needles and 
aggressive vaccination campaigns against HBV have assisted 
in the control of HBV infection and the spread of HDV 
infection.30
Most notably, this study shows a dramatic increase in 
positive HDV serology (17.3%) among HBV carriers com-
pared with the study conducted in the same region almost 
a decade ago. Amini et al found this to be 2.4% in 
Hamedan in 1993 (n = 123).19 Considering the declining 
trend of HDV in the world, the reasons behind this in-
crease are yet to be determined and further studies in this 
field are required.
In this study, factors such as age, sex, chronic hepatitis 
or carrier state, liver enzymes and positive HBeAg serol-
ogy did not have any association with positive anti-HDV 
serology, which corresponds to the previous studies car-
ried out in this field.25,31 There was a significant associa-
tion between HDV positivity and the mother’s hepatitis B 
carrier status. One of the most significant routes of trans-
mission for hepatitis B in Iran may be the horizontal route 
such as household contact. Following mandatory active 
immunization of newborns since 1993, vertical transmis-
sion of hepatitis B has dramatically dropped. It is thought 
that most patients with a history of mother carrier state 
of hepatitis B were born before the commencement of na-
tional immunization against hepatitis B, or they received 
the HBsAg via the horizontal route. This study needs to 
be repeated with a larger population to confirm the rela-
tionship between HDV antibody positivity and HBsAg 
positivity in mothers.
In conclusion, it is of utmost importance for healthcare 
providers and policy makers to recognize the risk factors 
associated with HBV and HDV co-infection and the reasons 
behind this regional increase in anti-HDV serology in HBV 
carriers, to control and contain this health problem.
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